This website is intended for Healthcare Professionals outside of the UK and the US.

Severity Cover Desktop

Severity Classification

Protein C deficiency severity is determined by the remaining
Protein C activity level

Mean protein C (PC) levels in healthy individuals1

10.scpcd Desktop Severity Maquette 1250Px

The severity of PC deficiency is determined by the remaining PC activity level. In healthy individuals, PC levels increase with age, with activity levels of 65–135 IU/dL considered to be normal for an adult.1



According to Goldenberg et al., adults with PC activity levels between 20 and 65 IU/dL are regarded as having mild PC deficiency, while moderately severe PC deficiency occurs when activity is between 1 and 20 IU/dL.1

Severe deficiency is defined by PC activity lower than 1 IU/dL.1 People with congenital PC deficiency caused by homozygous or compound heterozygous mutations have severe deficiency (SCPCD), whereas those with heterozygous mutations tend to have mild/moderate PC deficiency,1,2 with plasma PC activity being about half of the normal level of activity.3

Learn more about which tests can help confirm SCPCD

Protein C Activity Level (IU/dL)1*
No deficiency
Moderately severe
< 1

*Adult levels


  1. Goldenberg N, Manco-Johnson M. Protein C deficiency. Haemophilia. 2008;14(6):1214–1221.

  2. Chalmers E, et al. Purpura fulminans: recognition, diagnosis and management. Archives of Disease in Childhood. 2011;96(11):1066-1071.

  3. Marlar RA, et al. Report on the diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the ICTH-Subcommittee on Protein C and Protein S. Thromb Haemost. 1989;61(3):529-31.

SCPCD - ACTION TOOL Decision White (2)

Interested in Severe Congenital Protein C Deficiency (SCPCD) and its management?
Sign up below!

Sorry! There are some errors below that need to be fixed.
There seems to have been an error when sending the form.

You have the right to opt out of receiving such electronic communications at any time by using the opt out link in the communication you will receive or by contacting us at For more information on how Shire processes your personal data, please refer to our Privacy Notice.

Please include @ in your email adress


Thank you for submitting your details

You are about to leave this website. Shire has no influence or control over the content of this third party website.
Continue Cancel
This site is intended for healthcare professionals outside of the US and UK. Please verify that you are a healthcare professional by checking one of the boxes below :
Please tick the boxes to enter the site

Yes, I am a healthcare professional outside of the US and UK


No, I am not a healthcare professional outside of the US and UK